Blue Jet Healthcare IPO GMP: Are you confused to apply or not apply?

Is this a promoter sell off IPO or a chance for retail investors to jump in?

Blue Jet Healthcare deals with artificial sweetners, contrast media intermediates, & other pharma synthesis

Currently promoters hold 100% of Blue Jet Healthcare. Post IPO, it will be around 86%.

Grey Market Price (GMP) for BLUE JET is now currently at a premium of Rs. 60 which was Rs. 90 at the initial offering.

Many users are confused as how to sell IPO shares if allotted. Check the link below to learn how to sell Blue Jet IPO allotted shares.

Major firms recommended subscribe the Blue Jet Healthcare IPO. Next slides will show which firms recommended what.

Choice Broking on Blue Jet Healthcare:  Subscribe

Given 50% increase in capacity, & healthy RoE, Blue Jet Healthcare will have a healthy operating capacity for future growth.

Reaons: strong business prospects, healthy return ratios, forward integration, greenfield expansion plans and promising industry outlook.

GeoJit: Subscribe for medium to long term.

Mehta Equities on Blue Jet Healthcare IPO: Subscribe

Reasons: Long term contracts, with a 37% revenue and 34% profit growth in 2022, compared to 5.49% and -12% in 2023.

Stoxbox on Blue Jet Healthcare IPO: Subscribe

CAGR of 20.2%, with strong RoE and ROCE of 26.6% and 31.9%, respectively. Further, the growth in the CDMO model, robust financial performance and expanding production capacity.

What do you think? (a) Promoters will further continue selling off after listing. (b) No, promoters will continue holding.

Don't have a demat account yet ? Click on the link below to open a demat account to apply to Blue Jet Healthcare IPO.